Serum uric acid levels in patients with Parkinson's disease: Their relationship to treatment and disease duration

Andreadou, Elisabeth; Nikolaou, Chryssoula; Gournaras, Filippos; Rentzos, Michael; Boufidou, Fotini; Tsoutsou, Anthoussa; Zournas, C.; Zissimopoulos, Vassilis; Vassilopoulos, Demetrios

doi:10.1016/j.clineuro.2009.06.012

Cited by 123 publications

(121 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The association of low-normal serum urate levels with Parkinson's disease and multiple sclerosis has led to proposals that higher PUA protects neurons from toxic effects of peroxynitrite (7,(41)(42)(43). However, urate concentration in brain is much lower than in plasma (7,44,45); urate is a poor scavenger of peroxynitrite (46)(47)(48); and reactions of urate with free radicals have pro-as well as antioxidant consequences (46,47,49,50).…”

Section: Discussionmentioning

confidence: 99%

Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo

Hershfield

Roberts²,

Ganson³

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

121

View full text Add to dashboard Cite

A high plasma urate concentration (PUA), related to loss of urate oxidase in evolution, is postulated to protect humans from oxidative injury. This hypothesis has broad clinical relevance, but support rests largely on in vitro data and epidemiologic associations. Pegloticase therapy generates H 2 O 2 while depleting urate, offering an in vivo test of the antioxidant hypothesis. We show that erythrocytes can efficiently eliminate H 2 O 2 derived from urate oxidation to prevent cell injury in vitro; during therapy, disulfide-linked peroxiredoxin 2 dimer did not accumulate in red blood cells, indicating that their peroxidase capacity was not exceeded. To assess oxidative stress, we monitored F2-Isoprostanes (F2-IsoPs) and protein carbonyls (PC), products of arachidonic acid and protein oxidation, in plasma of 26 refractory gout patients receiving up to five infusions of pegloticase at 3-wk intervals. At baseline, PUA was markedly elevated in all patients, and plasma F2-IsoP concentration was elevated in most. Pegloticase infusion rapidly lowered mean PUA to ≤1 mg/dL in all patients, and PUA remained low in 16 of 21 patients who completed treatment. F2-IsoP levels did not correlate with PUA and did not increase during 15 wk of sustained urate depletion. There also was no significant change in the levels of plasma PC. Because refractory gout is associated with high oxidative stress in spite of high PUA, and profoundly depleting uric acid did not increase lipid or protein oxidation, we conclude that urate is not a major factor controlling oxidative stress in vivo.

show abstract

Section: Discussionmentioning

confidence: 99%

Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo

Hershfield

Roberts²,

Ganson³

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

121

View full text Add to dashboard Cite

show abstract

“…Sun et al. (2012) observed an inverse correlation between UA levels and disease severity in PD patients, but other studies have not (Andreadou et al., 2009). A recent cross‐sectional study found that decreased serum UA levels predicted the development of wearing‐off in patients with PD (Fukae et al., 2014).…”

Section: Discussionmentioning

confidence: 99%

Serum uric acid levels in Parkinson's disease and related disorders

et al. 2016

View full text Add to dashboard Cite

ObjectiveSerum uric acid (UA) levels are reported to be decreased in patients with Parkinson's disease (PD) and multiple system atrophy (MSA). However, clinical correlates of serum UA levels are still unclear in PD‐related disorders. We conducted a cross‐sectional study to evaluate the associations between serum UA levels and disease duration, disease severity, and motor function among PD, MSA, and progressive supranuclear palsy (PSP) patients.MethodsA total of 100 patients with PD, 42 patients with MSA, 30 patients with PSP, and 100 controls were included in this study. Serum UA levels were determined, and associations among serum UA levels and disease duration, disease severity, and motor function in PD, PSP, and MSA patients were evaluated.ResultsSerum UA levels were significantly lower in male PD, MSA, and PSP patients compared with the controls, but not in female patients. Serum UA levels were negatively correlated with disease duration and severity in MSA and PSP patients, but no correlations were observed in PD patients. The serum UA levels were significantly decreased in the tauopathy group (PSP patients) compared with the synucleinopathy group (PD and MSA patients) after adjusting for age, gender, and body mass index.ConclusionWe found decreased serum UA levels in male patients with PD‐related disorders (PD, MSA, and PSP) compared with male controls, and significant correlations between serum UA levels and disease severity in MSA and PSP patients.

show abstract

“…Several groups have reported a correlation between decreased plasma uric acid concentrations and clinical progression and stage of PD (39)(40)(41)(42)(43)(44)(45). Conversely, high plasma uric acid concentrations in hyperuricemia may reduce the risk and delay the progression of PD, but it increases the risk of cardiac diseases (46).…”

Section: Abundance Of Spontaneous Silkworm Mutant Stocks In Japanmentioning

confidence: 99%